Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial - PubMed
3 hours ago
- #hidradenitis suppurativa
- #interleukin antagonist
- #clinical trial
- Lutikizumab, a dual-variable domain interleukin 1α/1β antagonist, was tested in adults with moderate to severe hidradenitis suppurativa (HS) who failed anti-TNF therapy.
- The phase 2 randomized clinical trial involved 153 participants across 45 sites in 8 countries, with a 16-week treatment period.
- Participants were randomized into four groups: lutikizumab 300 mg weekly, 300 mg every other week, 100 mg every other week, or placebo.
- Primary endpoint was achieving HiSCR 50 at week 16, with secondary objectives including pain reduction and quality of life improvements.
- Results showed positive treatment effects for lutikizumab 300 mg weekly and every other week compared to placebo, with no serious adverse events reported.
- The study concluded that lutikizumab could be effective for HS patients who have failed anti-TNF therapy.